<SEC-DOCUMENT>0001193125-18-116086.txt : 20180413
<SEC-HEADER>0001193125-18-116086.hdr.sgml : 20180413
<ACCEPTANCE-DATETIME>20180413070255
ACCESSION NUMBER:		0001193125-18-116086
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20180411
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20180413
DATE AS OF CHANGE:		20180413

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			INOVIO PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0001055726
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				330024450
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-14888
		FILM NUMBER:		18753142

	BUSINESS ADDRESS:	
		STREET 1:		10480 WATERIDGE CIRCLE
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		858 597-6006

	MAIL ADDRESS:	
		STREET 1:		10480 WATERIDGE CIRCLE
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INOVIO BIOMEDICAL CORP
		DATE OF NAME CHANGE:	20050404

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GENETRONICS BIOMEDICAL CORP
		DATE OF NAME CHANGE:	20011116

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GENETRONICS BIOMEDICAL LTD
		DATE OF NAME CHANGE:	19980213
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d570655d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, DC 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">8-K</FONT></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT
REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to Section&nbsp;13 or 15(d) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of The Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): April&nbsp;11, 2018 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Inovio Pharmaceuticals, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">001-14888</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">33-0969592</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Commission File Number)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>660 W. Germantown Pike, Suite 110 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Plymouth Meeting, PA 19462 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive offices, including zip code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(267) <FONT STYLE="white-space:nowrap">440-4200</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Registrant&#146;s telephone number, including area code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former name or
former address, if changed since last report) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below
if the Form <FONT STYLE="white-space:nowrap">8-K</FONT> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule <FONT STYLE="white-space:nowrap">14a-12</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.14a-12)</FONT> </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to Rule <FONT STYLE="white-space:nowrap">14d-2(b)</FONT> under the Exchange Act (17 CFR
<FONT STYLE="white-space:nowrap">240.14d-2(b))</FONT> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to Rule <FONT STYLE="white-space:nowrap">13e-4(c)</FONT> under the Exchange Act (17 CFR
<FONT STYLE="white-space:nowrap">240.13e-4(c))</FONT> </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Securities Exchange Act of 1934 <FONT STYLE="white-space:nowrap">(&#167;240.12b-2</FONT> of this chapter).
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;13(a) of the Exchange
Act.&nbsp;&nbsp;&#9744; </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;8.01</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Other Events. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&nbsp;11, 2018, Inovio Pharmaceuticals, Inc. (the &#147;Registrant&#148;)
announced that it has entered into agreements with the Coalition for Epidemic Preparedness Innovations, or CEPI, pursuant to which the Registrant intends to develop vaccine candidates against Lassa fever and Middle East Respiratory Syndrome, or
MERS. The goal of the collaboration between the Registrant and CEPI is to unlock research and development potential so that investigational stockpiles will be ready for clinical efficacy trial testing during potential disease outbreaks. The
agreements with CEPI contemplate <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies, as well as Phase 1 and Phase 2 clinical trials, occurring over the next few years. As part of the arrangement between the parties, CEPI has agreed to fund
up to an aggregate of $56&nbsp;million of costs over a five-year period for preclinical studies, as well as planned Phase 1 and Phase 2 clinical trials, to be conducted by the Registrant, with funding from CEPI based on the achievement of identified
milestones. The Registrant&#146;s vaccine candidate for Lassa fever will be known as <FONT STYLE="white-space:nowrap">INO-4500,</FONT> and its vaccine candidate for MERS will be known as <FONT STYLE="white-space:nowrap">INO-4700.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&nbsp;11, 2018, the Registrant issued a press release announcing the funding agreements with CEPI. A copy of this press release is filed as Exhibit
99.1 to this Current Report on Form <FONT STYLE="white-space:nowrap">8-K.</FONT> </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;9.01</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Financial Statements and Exhibits. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(d) Exhibits </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:28.45pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:66.80pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Exhibit
Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d570655dex991.htm">Press Release, dated April&nbsp;11, 2018, &#147;Inovio Awarded up to $56 Million from CEPI to Advance DNA Vaccines Against Lassa Fever and MERS.&#148;</A></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Current Report contains certain forward-looking statements relating to the agreements entered into between Inovio and CEPI and the funding, anticipated
benefits and clinical trials contemplated under such agreements. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in
<FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies, clinical trials and product development programs, the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation
technology as a delivery mechanism or develop viable DNA vaccines, our ability to support our pipeline of SynCon<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> active immunotherapy and vaccine products, the ability of our collaborators to
attain development and commercial milestones for products we license and product sales that will enable us to receive future payments and royalties, the adequacy of our capital resources, the availability or potential availability of alternative
therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost effective than any therapy or treatment that the company and its collaborators hope to develop,
issues involving product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or
defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of
corporate expenditures, assessments of the company&#146;s technology by potential corporate or other partners or collaborators, capital market conditions, the impact of government healthcare proposals and other factors set forth in our Annual Report
on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2017 and other regulatory filings we make from time to time. There can be no assurance that any product candidate in the Registrant&#146;s pipeline will be
successfully developed, manufactured or commercialized, that final results of clinical trials will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be
proven accurate. Forward-looking statements speak only as of the date of this release, and the Registrant undertakes no obligation to update or revise these statements, except as may be required by law. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"><B>INOVIO PHARMACEUTICALS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: April&nbsp;11, 2018</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Peter Kies</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Peter Kies</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Financial Officer</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d570655dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g570655g0412172613434.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">


<IMG SRC="g570655g0412172613652.jpg" ALT="LOGO">
</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>NEWS RELEASE </I></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>FOR IMMEDIATE
RELEASE </B></P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Inovio Awarded up to $56 Million from CEPI </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>to Advance DNA Vaccines Against Lassa Fever and MERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Major investment by Coalition for Epidemic Preparedness Innovations (CEPI) to advance vaccine development and manufacturing on two of
CEPI&#146;s highest priority infectious diseases </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PLYMOUTH MEETING, Pa. (USA) and OSLO, Norway &#150; April&nbsp;11, 2018 &#150; Inovio
Pharmaceuticals, Inc. (NASDAQ: INO) and CEPI &#150; the Coalition for Epidemic Preparedness Innovations &#151; today announced a partnership under which Inovio will develop vaccine candidates against Lassa fever and Middle East Respiratory Syndrome
(MERS). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CEPI will fund up to $56,000,000 to support Inovio&#146;s <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and clinical
advancement&nbsp;through Phase 2 of <FONT STYLE="white-space:nowrap">INO-4500,</FONT> its Lassa fever vaccine, and <FONT STYLE="white-space:nowrap">INO-4700,</FONT> its MERS vaccine.&nbsp;The shared goal of Inovio and CEPI is for the Lassa and MERS
vaccines to be available as soon as possible for emergency use. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This is the second company agreement CEPI has signed since its launch in 2017. These
partnerships represent an innovative approach to funding vaccine development, unlocking research and development potential so that vaccines are ready for efficacy studies during an outbreak. The agreement will enable funding for Inovio&#146;s
development efforts over a five-year period. The partnership agreement also includes options, not counted in the total above, to establish investigational stockpiles of both vaccines. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lassa fever is a disease endemic to West Africa associated with annual outbreaks. An ongoing outbreak in Nigeria has, according to figures from the Nigerian
Centre for Disease Control, resulted in over 400 confirmed cases and over 100 deaths from January<U></U>&nbsp;1, 2018 through April&nbsp;8, 2018<SUP STYLE="font-size:85%; vertical-align:top">1</SUP>. MERS, first identified in 2012, causes a severe
respiratory illness and has been associated with a number of outbreaks in Saudi Arabia and neighboring countries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Individuals acquiring these diseases in
the regions of origin occasionally travel to other locations, becoming ill in areas outside the endemic regions. In 2015 an individual with MERS returned to South Korea from the Middle East. This resulted in an outbreak that resulted in 186
confirmed cases and 38 deaths. The outbreak affected 24 hospitals, led to the temporary closure of more than 2,000 schools, and had a significant impact on the South Korean economy. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">http://ncdc.gov.ng/diseases/sitreps/?cat=5&amp;name=An update of Lassa fever outbreak in Nigeria </TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Richard Hatchett, CEO of CEPI said: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Epidemics don&#146;t respect borders; they destroy lives and devastate economies and we need to move swiftly to prepare for them. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Partnering with Inovio is a considerable move forward for CEPI&#146;s vaccine portfolio and developing a global insurance policy against these
diseases.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CEPI&#146;s funding will support development up to the end of Phase 2, providing clinical safety and immunological data, and the
establishment of investigational stockpiles that will be ready for clinical efficacy trial testing during outbreaks. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CEPI&#146;s portfolio of investments
will provide additional benefits to the wider vaccine community through the development of assays, reference standards and associated knowledge that may accelerate the development of other vaccines and medical counter measures against Lassa fever
and MERS. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;J. Joseph Kim, Inovio&#146;s President&nbsp;&amp; CEO, said: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;The Inovio/CEPI partnership demonstrates the confidence of both organizations in Inovio&#146;s DNA vaccine platform to rapidly produce countermeasures
against emerging viral threats potentially protecting large populations from a pandemic. A key demonstration of such capabilities was that Inovio was the first organization to develop, manufacture and report positive human data from a Zika vaccine
in less than seven months &#150; when traditional vaccines take several years to reach this point. We look forward to addressing the global health challenges of emerging infectious diseases.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Inovio will develop these DNA vaccines employing its ASPIRE&#153; (Antigen SPecific Immune REsponses) platform. This platform delivers optimized synthetic
antigenic genes into cells, where they are translated into protein antigens that activate an individual&#146;s immune system to generate robust targeted T cell and antibody responses. Inovio&#146;s immunotherapies function exclusively <I>in
vivo</I>, and have generated an antigen-specific immune response against targeted diseases in all clinical trials to date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The CEPI partnership builds
upon Inovio&#146;s clinical and preclinical advancements for MERS and Lassa fever vaccines. Results from a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> Phase 1 study for its MERS vaccine found high
levels of binding antibodies in 92% (57 of 62) of evaluated subjects. Significant antigen-specific cytotoxic <FONT STYLE="white-space:nowrap">T-lymphocyte</FONT> (CTL) responses were also observed. Importantly, all but one evaluated vaccinated
subject or 98% (61 of 62) generated an antibody and/or T cell response against the MERS vaccine. Inovio&#146;s Lassa vaccine data also holds much promise<SUP STYLE="font-size:85%; vertical-align:top">2</SUP>. In a study funded by a $3.5&nbsp;million
grant from the National Institute of Allergy and Infectious Diseases (NIAID), Inovio previously published that its DNA vaccine against Lassa fever provided 100% protection for <FONT STYLE="white-space:nowrap">non-human</FONT> primates challenged
with a lethal dose of the virus<SUP STYLE="font-size:85%; vertical-align:top">3</SUP>. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">2</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">http://ir.inovio.com/news-and-media/news/press-release-details/2017/Inovio-Reports-New-Positive-
</FONT></FONT></FONT></FONT>
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Clinical-Data-on-Vaccine-Advances--in-the-Fight-Against-Emerging-Infectious-Diseases/default.aspx
</FONT></FONT></FONT></FONT></FONT> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">3</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">http://ir.inovio.com/news-and-media/news/press-release-details/2015/Inovio-Pharmaceuticals-DNA-
</FONT></FONT></FONT></FONT>
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Vaccine-Protects-100-Against-Deadly-MERS-Virus-in-Non-Human-Primates/default.aspx</FONT>
</FONT></FONT></FONT></FONT> </TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Inovio is advancing MERS and Lassa vaccines with the support of its collaborators: The Wistar Institute, Laval
University, the NIH&#146;s Rocky Mountain Laboratories, U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), VGXI/GeneOne Life Science and the International Vaccine Institute. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About MERS </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Middle East Respiratory Syndrome is caused by
the MERS-Corona virus, part of the same family of viruses that causes the common cold and SARS (Severe Acute Respiratory Syndrome). It is transmitted from animals to humans and can be further transmitted by person to person contact. Symptoms include
severe acute respiratory illness with fever, cough and shortness of breath as well as gastrointestinal symptoms, which can lead to death. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Lassa
Fever </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lassa fever is also known as Lassa hemorrhagic fever. The Lassa virus is transferred to humans from animals, most commonly by the
<I>Mastomys</I> rodent. The virus can spread from person to person via bodily fluids and causes a range of symptoms including vomiting, swelling of the face, bleeding, and pain in the chest, back and abdomen. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About CEPI </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CEPI is an innovative partnership between
public, private, philanthropic and civil organizations founded in Davos in 2017. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To date, CEPI has received multi-year funding from Norway, Germany,
Japan the Bill&nbsp;&amp; Melinda Gates Foundation and Wellcome. CEPI has also received single-year investments from the governments of, Australia, Belgium, and Canada. It has reached $630&nbsp;million of its target $1&nbsp;billion funding target.
The European Commission has announced a contribution in kind of &#128;250&nbsp;million that will support relevant projects through EC mechanisms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since
its launch in January 2017, CEPI has announced two Calls for Proposals. The first was for candidate vaccines against <FONT STYLE="white-space:nowrap">MERS-COV,</FONT> Nipah and Lassa viruses. The second was for the development of platforms that can
be used for rapid vaccine development against unknown pathogens. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Inovio Pharmaceuticals, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Inovio is taking immunotherapy to the next level in the fight against cancer and infectious diseases. We are the only immunotherapy company that has reported
generating CD8+ T cells in vivo in high quantity that are fully functional and whose killing capacity correlates with relevant clinical outcomes with a favorable safety profile. With an expanding portfolio of immune therapies, the company is
advancing a growing clinical stage product pipeline, including candidates in Phase 3 and Phase 2. Partners and collaborators include MedImmune, Regeneron, Genentech, The Wistar Institute, University of Pennsylvania, the Parker Institute for Cancer
Immunotherapy, DARPA, GeneOne Life Science, Plumbline Life Sciences, ApolloBio Corporation, Drexel University, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program, and Laval University. For more
information, visit <U>www.inovio.com</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">* * * </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This press release contains certain forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene
delivery technologies and DNA vaccines, our expectations regarding our research and development programs, including the planned initiation and conduct of clinical </I></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>
trials and the availability and timing of data from those trials, and the sufficiency of our capital resources. Actual events or results may differ from the expectations set forth herein as a
result of a number of factors, including uncertainties inherent in <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies, clinical trials and product development programs, the availability of funding to support continuing research and studies
in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, our ability to support our pipeline of SynCon<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> active
immunotherapy and vaccine products, the ability of our collaborators to attain development and commercial milestones for products we license and product sales that will enable us to receive future payments and royalties, the adequacy of our capital
resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost effective than any therapy or
treatment that the company and its collaborators hope to develop, issues involving product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered
technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other significant resources that
may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company&#146;s technology by potential corporate or other partners or collaborators, capital market conditions, the impact of government
healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December&nbsp;31, 2017 and other regulatory filings we make from time to time. There can be no assurance that any product candidate in
Inovio&#146;s pipeline will be successfully developed, manufactured or commercialized, that final results of clinical trials will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking
information provided herein will be proven accurate. Forward-looking statements speak only as of the date of this release, and Inovio undertakes no obligation to update or revise these statements, except as may be required by law. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contacts </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>For CEPI </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Rachel Grant </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Phone: +44(0)7891249190 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Email: Rachel.Grant@cepi.net </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>For Inovio </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investors: </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ben Matone </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Phone: <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">484-362-0076,</FONT></FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Email: ben.matone@inovio.com </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Media: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jeff Richardson </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Phone: <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">267-440-4211</FONT></FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Email: jrichardson@inovio.com </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g570655g0412172613434.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g570655g0412172613434.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !5 'P# 2(  A$! Q$!_\0
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0HE^ZB+@#\***+L$DG<__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g570655g0412172613652.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g570655g0412172613652.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !6 .H# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#WB\NX;&SF
MNKAML,2%W/L*Y&P^(MI=ZE';364D$4KA$E+@X)Z;ACC\S75:G81ZIIEQ8RL5
M29"I8=1Z&N"T[X=WR:I&U[<0?98W#$QDEGP<XQCB@#TBBBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** $=UC1G<@*HR2>PKB/^%E67V[9]BE^
MR;L>?O&<?WMOI^-=K-$L\$D+C*2*5;Z$8KS7_A6U_P#;O*^UP?8]W^MYW[?]
MW'7\: /3%97174@JPR".XI:9#$L$,<2#"(H5?H.*?0 4444 %%%% !1110 A
M( ))P!U-4X=7TVXE6*'4+621N%1)E)/T&:LW'_'M+_N'^5>-^#P/^$KTWC_E
MH?\ T$T >T55N=2L+.01W-[;PN1D+)(%./7FK5>6?$?_ )&.'_KV7_T)J /3
M#>VHM/M9N8A;8W>;O&W'UZ5CMXU\/*^W^T4/N$8C\\5Y[I]GJ_BM;?3X"%M+
M*,+EB0B>Y]6-;4OPSN5A)BU*)Y<?=:(J#^.3_*@#OK+4+/48?-L[F*=.Y1LX
M^OI5FO$;.[OO#&N;]K1SP/MFBSPZ]P?4$=#]#7M4$R7%O'-&<I(H=3Z@C(H
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MV;PTR J3@X!!(_&JEAJ&J3>-FM;Z 6L0T[S%A2X\U6;S,;ONC!QQ3YEV_/\
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M.9DBGDG$J \/B(D9^AYJ]J]S<66C7UU:0^?<PV[R118)WL%) X]31S+M^?\
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M83<?4XI;W3[/4H!#?6L-S$#N"2H& /KSWHHH FBBC@A2&&-(XD 5$10 H'0
(#H*?110!_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
